GeoVax Secures EMA Advice for Phase 3 Immunobridging of MVA Vaccine, Trial Q4 2026
GOVX•GeoVax received positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway for its GEO-MVA smallpox and mpox vaccine candidate. The pivotal trial is slated to start in Q4 2026, with topline immunogenicity data expected by mid-2027.
1. EMA Scientific Advice and Phase 3 Pathway
GeoVax announced that the European Medicines Agency granted positive Scientific Advice for an immunobridging pathway in its pivotal Phase 3 trial of GEO-MVA, its Modified Vaccinia Ankara-based mpox and smallpox vaccine candidate. This guidance charts a regulatory path to potential approval, with trial initiation scheduled for Q4 2026 and topline immunogenicity results anticipated by mid-2027.
2. Strategic Focus on Domestic MVA Manufacturing
Company leadership highlighted the importance of scalable, flexible domestic MVA-based vaccine manufacturing to bolster biodefense readiness and diversify global supply chains. GeoVax intends to leverage these developments to enhance long-term preparedness infrastructure and reduce reliance on reactive outbreak cycles.
3. GEO-MVA Vaccine Candidate Details
GEO-MVA is designed as a next-generation MVA vaccine to address orthopoxvirus threats by expanding global supply and manufacturing capabilities. The program benefits from an expedited regulatory pathway and aims to differentiate itself through scalability, diversified production, and strong immunogenicity profiles.
